Systems and methods of providing modulation therapy without patient-perception of stimulation

Abstract

A neuromodulation system and method of providing sub-threshold modulation therapy. Electrical modulation energy is delivered to a target tissue site of the patient at a programmed intensity value, thereby providing therapy to a patient without perception of stimulation. In response to an event, electrical modulation energy is delivered at incrementally increasing intensity values. At least one evoked compound action potential (eCAP) is sensed in a population of neurons at the target tissue site of the patient in response to the delivery of the electrical modulation energy at the incrementally increasing intensity values. One of the incrementally increased intensity values is selected based on the sensed eCAP(s). A decreased intensity value is automatically computed as a function of the selected intensity value. Electrical modulation energy is delivered to the target tissue site of the patient at the computed intensity value, thereby providing sub-threshold therapy to the patient.

Description

CLAIM OF PRIORITY[0001]This application claims the benefit of priority under 35 U.S.C. §119(e) of U.S. Provisional Patent Application Ser. No. 61 / 858,730, filed on Jul. 26, 2013, which is herein incorporated by reference in its entirety.FIELD OF THE INVENTION[0002]The present inventions relate to tissue modulation systems, and more particularly, to programmable neuromodulation systems.BACKGROUND[0003]Implantable neuromodulation systems have proven therapeutic in a wide variety of diseases and disorders. Pacemakers and Implantable Cardiac Defibrillators (ICDs) have proven highly effective in the treatment of a number of cardiac conditions (e.g., arrhythmias). Spinal Cord Stimulation (SCS) systems have long been accepted as a therapeutic modality for the treatment of chronic pain syndromes, and the application of tissue stimulation has begun to expand to additional applications such as angina pectoralis and incontinence. Deep Brain Stimulation (DBS) has also been applied therapeutical...

AI Technical Summary

Benefits of technology

The present invention provides a method and system for providing therapy to a patient without the perception of paresthesia. The method involves delivering electrical modulation energy to a target tissue site of the patient at a programmed intensity value, and sensing an evoked compound action potential (eCAP) in a population of neurons in response to the delivery of the electrical modulation energy. The method includes automatically computing a decreased intensity value based on the eCAP and delivering electrical modulation energy to the target tissue site at the computed intensity value. The system includes a plurality of electrical terminals, modulation output circuitry, and control / processing circuitry. The technical effects of the invention include providing therapy without the perception of paresthesia, improved efficacy of therapy, and reduced risk of injury during therapy.

Problems solved by technology

However, the number of electrodes available combined with the ability to generate a variety of complex electrical pulses, presents a huge selection of modulation parameter sets to the clinician or patient.

Thus, correct lead placement can mean the difference between effective and ineffective pain therapy.

Although alternative or artifactual sensations are usually tolerated relative to the sensation of pain, patients sometimes report these sensations to be uncomfortable, and therefore, they can be considered an adverse side-effect to neuromodulation therapy in some cases.

However, because there is a lack of paresthesia that may otherwise indicate that the activated electrodes are properly located relative to the targeted tissue site, it is difficult to immediately determine if the delivered sub-threshold neuromodulation therapy is optimized in terms of both providing efficacious therapy and minimizing energy consumption.

Furthermore, if the implanted neuromodulation lead(s) migrate relative to the target tissue site to be modulated, it is possible that the sub-threshold neuromodulation may fall outside of the effective therapeutic range (either below the therapeutic range if the coupling efficiency between the neuromodulation lead(s) and target tissue site decreases, resulting in a lack of efficacious therapy, or above the therapeutic range if the coupling efficiency between the neuromodulation lead(s) and the target tissue site increases, resulting in the perception of paresthesia or inefficient energy consumption).

Similarly, a change in the patient's physical activity and / or posture may also cause the neuromodulation lead(s) to migrate relative to the target tissue, and / or alternatively impede optimal treatment contact to the target tissue, consequently rendering the sub-threshold neuromodulation therapy inefficacious.

Images